Pliant Therapeutics appoints Katharine Knobil to Board, amends bylaws

PLIANT THERAPEUTICS, INC.

Dr. Katharine Knobil appointed to newly created Board seat; term expires at 2025 annual meeting.
Knobil will serve on R&D Committee; qualifies as independent director.
She receives option for 30,000 shares vesting over 3 years, annual retainer $39,000 prorated.
Board approved Second Amended and Restated Bylaws with enhanced shareholder proposal requirements and emergency procedures.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Katharine Knobil

Director

PLRX · PLIANT THERAPEUTICS, INC.

Effective: 2022-09-14
Filed: September 16, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, Dr. Katharine Knobil to fill a newly created Board seat

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Katharine Knobil was appointed as Director at PLIANT THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, Dr. Katharine Knobil to fill a newly created Board seat

View on SEC.gov

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-246364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.